2. Academic Validation
  3. ZMIZ2 facilitates hepatocellular carcinoma progression via LEF1 mediated activation of Wnt/β-catenin pathway

ZMIZ2 facilitates hepatocellular carcinoma progression via LEF1 mediated activation of Wnt/β-catenin pathway

  • Exp Hematol Oncol. 2024 Jan 22;13(1):5. doi: 10.1186/s40164-024-00475-w.
Yang Ding # 1 2,  Yumei Ning # 1 2,  Hui Kang # 1 2,  Yuan Yuan 1 2,  Kun Lin 1 2,  Chun Wang 1 2,  Yun Yi 1 2,  Jianghua He 1 2,  Lurao Li 1 2,  Xingxing He 3 4,  Ying Chang 5 6
Affiliations

Affiliations

  • 1 Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
  • 2 Hubei Clinical Center and Key Laboratory of Intestinal and Colorectal Diseases, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
  • 3 Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. [email protected].
  • 4 Hubei Clinical Center and Key Laboratory of Intestinal and Colorectal Diseases, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. [email protected].
  • 5 Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. [email protected].
  • 6 Hubei Clinical Center and Key Laboratory of Intestinal and Colorectal Diseases, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. [email protected].
  • # Contributed equally.
PMID: 38254216 DOI: 10.1186/s40164-024-00475-w
Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies with a high lethality rate. ZMIZ2 is a transcriptional co-activator implicated in various human diseases. However, the role and molecular mechanism of ZMIZ2 in HCC remains to be elucidated.

Methods: The expression and prognostic value of ZMIZ2 in HCC was excavated from public databases and explored by bioinformatic analysis. Then the expression of ZMIZ2 and related genes was further validated by quantitative RT-PCR, western blotting, and immunohistochemistry. Loss and gain-of-function experiments were performed in vitro and in vivo to investigate the function of ZMIZ2 in HCC. In addition, transcriptome sequencing and immunoprecipitation was conducted to explore the potential molecular mechanisms of ZMIZ2.

Results: ZMIZ2 was highly expressed in HCC and associated with poor prognosis. Silencing ZMIZ2 significantly inhibited HCC cell proliferation, cell cycle process, migration, and invasion in vitro, and also inhibited the progression of HCC in vivo. Additionally, ZMIZ2 expression was correlated with immune cell infiltration in HCC samples. Somatic mutation analysis showed that ZMIZ2 and TP53 mutations jointly affected the progression of HCC. Mechanistically, ZMIZ2 interacted with LEF1 to regulate malignant progression of HCC by activating the Wnt/β-catenin pathway.

Conclusion: ZMIZ2 was overexpressed in HCC and associated with poor prognosis. The overexpression of ZMIZ2 was corelated with malignant phenotype, and it facilitated HCC progression via LEF1-mediated activation of the Wnt/β-catenin pathway. Furthermore, ZMIZ2 could be served as a prognostic biomarker and a new therapeutic target for HCC.

Keywords

Hepatocellular carcinoma; LEF1; Prognosis; Wnt/β-catenin pathway; ZMIZ2.

Figures
Products